Literature DB >> 30498718

Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005.

Mathilde Wisniewski1, Pierre-Alain Placide1, Sandra Granier1, Yacoub Al Shatti1, Shuaib Al Qalaf1, Mohamed Bouattour1, Michele Lamuraglia1, Pascal Hammel1.   

Abstract

Entities:  

Year:  2018        PMID： 30498718      PMCID： PMC6230846          DOI： 10.21037/hbsn.2018.08.03

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  15 in total

1.  Pancreatic adenocarcinoma.

Authors:  David P Ryan; Theodore S Hong; Nabeel Bardeesy
Journal:  N Engl J Med       Date:  2014-11-27       Impact factor: 91.245

2.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Authors:  J P Neoptolemos; J A Dunn; D D Stocken; J Almond; K Link; H Beger; C Bassi; M Falconi; P Pederzoli; C Dervenis; L Fernandez-Cruz; F Lacaine; A Pap; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

3.  Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies.

Authors:  Magali Svrcek; Jérôme Cros; Raphael Maréchal; Jean-Baptiste Bachet; Jean-François Fléjou; Pieter Demetter
Journal:  Histopathology       Date:  2014-12-22       Impact factor: 5.087

4.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Authors:  John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler
Journal:  Lancet       Date:  2017-01-25       Impact factor: 79.321

5.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

Authors:  John P Neoptolemos; Deborah D Stocken; Claudio Bassi; Paula Ghaneh; David Cunningham; David Goldstein; Robert Padbury; Malcolm J Moore; Steven Gallinger; Christophe Mariette; Moritz N Wente; Jakob R Izbicki; Helmut Friess; Markus M Lerch; Christos Dervenis; Attila Oláh; Giovanni Butturini; Ryuichiro Doi; Pehr A Lind; David Smith; Juan W Valle; Daniel H Palmer; John A Buckels; Joyce Thompson; Colin J McKay; Charlotte L Rawcliffe; Markus W Büchler
Journal:  JAMA       Date:  2010-09-08       Impact factor: 56.272

6.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

Authors:  Helmut Oettle; Peter Neuhaus; Andreas Hochhaus; Jörg Thomas Hartmann; Klaus Gellert; Karsten Ridwelski; Marco Niedergethmann; Carl Zülke; Jörg Fahlke; Michael B Arning; Marianne Sinn; Axel Hinke; Hanno Riess
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

7.  Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).

Authors:  Katsuhiko Uesaka; Narikazu Boku; Akira Fukutomi; Yukiyasu Okamura; Masaru Konishi; Ippei Matsumoto; Yuji Kaneoka; Yasuhiro Shimizu; Shoji Nakamori; Hirohiko Sakamoto; Soichiro Morinaga; Osamu Kainuma; Koji Imai; Naohiro Sata; Shoichi Hishinuma; Hitoshi Ojima; Ryuzo Yamaguchi; Satoshi Hirano; Takeshi Sudo; Yasuo Ohashi
Journal:  Lancet       Date:  2016-06-02       Impact factor: 79.321

8.  Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

Authors:  Eric Van Cutsem; Walter L Vervenne; Jaafar Bennouna; Yves Humblet; Sharlene Gill; Jean-Luc Van Laethem; Chris Verslype; Werner Scheithauer; Aijing Shang; Jan Cosaert; Malcolm J Moore
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

9.  Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.

Authors:  Juan W Valle; Daniel Palmer; Richard Jackson; Trevor Cox; John P Neoptolemos; Paula Ghaneh; Charlotte L Rawcliffe; Claudio Bassi; Deborah D Stocken; David Cunningham; Derek O'Reilly; David Goldstein; Bridget A Robinson; Christos Karapetis; Andrew Scarfe; Francois Lacaine; Juhani Sand; Jakob R Izbicki; Julia Mayerle; Christos Dervenis; Attila Oláh; Giovanni Butturini; Pehr A Lind; Mark R Middleton; Alan Anthoney; Kate Sumpter; Ross Carter; Markus W Büchler
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

10.  Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

Authors:  William Greenhalf; Paula Ghaneh; John P Neoptolemos; Daniel H Palmer; Trevor F Cox; Richard F Lamb; Elizabeth Garner; Fiona Campbell; John R Mackey; Eithne Costello; Malcolm J Moore; Juan W Valle; Alexander C McDonald; Ross Carter; Niall C Tebbutt; David Goldstein; Jennifer Shannon; Christos Dervenis; Bengt Glimelius; Mark Deakin; Richard M Charnley; François Lacaine; Andrew G Scarfe; Mark R Middleton; Alan Anthoney; Christopher M Halloran; Julia Mayerle; Attila Oláh; Richard Jackson; Charlotte L Rawcliffe; Aldo Scarpa; Claudio Bassi; Markus W Büchler
Journal:  J Natl Cancer Inst       Date:  2013-12-03       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.